- Home
- TAC vs RNA Comparison
TAC vs RNA Comparison
Compare TAC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | RNA |
|---|---|---|
| Founded | 1909 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TAC | RNA |
|---|---|---|
| Price | $12.71 | $72.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $21.63 | ★ $69.26 |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,783,342,546.00 | $20,868,000.00 |
| Revenue This Year | N/A | $64.11 |
| Revenue Next Year | N/A | $37.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 106.27 |
| 52 Week Low | $7.82 | $21.51 |
| 52 Week High | $17.88 | $72.61 |
Technical Indicators
Market Signals| Indicator | TAC | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 30.22 | 73.51 |
| Support Level | $12.34 | $71.99 |
| Resistance Level | $15.24 | $72.61 |
| Average True Range (ATR) | 0.52 | 0.28 |
| MACD | -0.11 | -0.37 |
| Stochastic Oscillator | 1.73 | 69.93 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.